Skip to main content
. 2017 May 2;49(5):1602238. doi: 10.1183/13993003.02238-2016

TABLE 3.

Proposed practical guidelines for adjusting maintenance medications during acute loss of asthma control

Recommendation Rationale Supporting evidence
Maintain the controller medication as part of the “yellow zone” dose, where possible Reinforces that “green zone” controller medications are never to be stopped and minimises chances of the patient continuing with the incorrect puffer after yellow zone treatment is complete Adherence shown to decrease when maintenance medications are changed [31, 32]
Add additional inhalations while maintaining the baseline controller medication frequency, where possible Minimises dosing frequency, maintains consistency with the controller regimen, thereby minimising medication errors and maximising adherence Adherence shown to be inversely correlated with dosing frequency [33, 34]
Increase the number of inhalations of the baseline controller medication to attain the target dose rather than prescribing an additional inhaler, where possible Minimises cost and complexity of filling a new inhaler prescription and maximises adherence Adherence shown to decrease when new inhalers are added or more than one inhaler is recommended [35, 36]
When it is necessary to add a new inhaler in the “yellow zone,” use the same device type as the baseline controller medication Maintains consistency with the baseline controller medication, thereby minimising medication administration errors and maximises adherence Adherence and asthma control shown to worsen when device type is changed [31]
Do not exceed 4 inhalations per use, and in cases where it is necessary to add a new puffer in the yellow zone, use a dose which favours the least number of inhalations per use Ensures practical applicability of yellow zone regimen, thereby maximising adherence MDI and DPI inhalers require up to 1 min per puff [36]
More than 4 min per use is not practical and may decrease adherence (expert opinion)
Consider patient-relevant issues such as medication cost and product shelf-life, particularly when proposing a requirement for new prescriptions in the “yellow zone” Excessive cost of treatment and the possibility of medication waste may negatively affect adherence Adherence has been shown to be inversely correlated with socioeconomic status and income in some studies [36]

MDI: metered dose inhaler; DPI: dry powder inhaler.